What is Alpha-Lipoic Acid?
Alpha-lipoic acid (ALA) is a sulfur-containing fatty acid that the body produces in small amounts and serves as a cofactor for mitochondrial enzymes. Its most distinctive feature is dual solubility: ALA is both water- and fat-soluble—this allows it to function as an antioxidant both inside cells and in cell membranes.
Unlike vitamins C and E, ALA is discussed not only as a direct antioxidant but also as a recycler of other antioxidants (glutathione, vitamin C, vitamin E, CoQ10)—which is why it is sometimes called a “universal antioxidant.” This recycling function makes it somewhat unique among supplements: it may help regenerate the antioxidant capacity of other compounds rather than simply mopping up free radicals on its own.
R-Form vs. S-Form: A Critical Distinction
Commercial ALA products often contain a racemic mixture—a 50:50 blend of R-ALA and S-ALA. Only the R-form occurs naturally in the body and demonstrates significantly higher bioavailability and efficacy in studies. The difference is not trivial: R-ALA reaches target tissues much more effectively than the S-form, and only R-ALA is actually incorporated into mitochondrial enzyme complexes.
R-ALA is more expensive to produce, but it is the biologically relevant form. Bottom line for purchasing: Products labeled simply as “alpha-lipoic acid” without specifying the form usually contain cheap racemic mixture. If the label does not explicitly say “R-ALA” or “R-alpha-lipoic acid,” assume you are getting half of an irrelevant enantiomer.
What the Research Actually Shows
Well-Established
- Diabetic neuropathy: Multiple RCTs demonstrate improvement in pain and sensory disturbances with both intravenous and oral administration. This is the strongest evidence base for ALA. A newer phase IV combination trial with pregabalin also adds more practice-oriented evidence in a real neuropathy setting. Studies typically used 300–600 mg/day orally or 600 mg intravenously, and benefits appeared after 3–4 weeks.
- Insulin sensitivity: Meta-analyses show reductions in fasting blood glucose and insulin levels in patients with metabolic dysfunction. The effect size is modest but meaningful—typically a 5–10% improvement in glucose control in people with metabolic syndrome or prediabetes.
- Inflammatory markers: CRP reduction demonstrated in RCTs in patients with metabolic disease. This aligns with ALA’s presumed antioxidant mechanism, though the clinical significance of modest CRP reductions remains unclear.
Promising but Early
- Neuroprotective effects: Animal models (particularly in Alzheimer’s disease) show that ALA can reduce neuroinflammation and support mitochondrial function. Human evidence is sparse and limited to small, short-duration studies.
- Weight reduction: Modest effects in some RCTs, though not consistent across all trials. When weight loss does occur, it may be secondary to improved glucose control rather than a direct metabolic effect.
- Mitochondrial biogenesis: Preclinical evidence suggests ALA activates PGC-1α and supports new mitochondrial formation, but this has not been rigorously tested in humans.
Not Demonstrated in Humans
- Direct aging-related effects: Despite ALA’s theoretical role in oxidative stress, no human studies have tested whether it extends healthspan or reverses aging-related decline.
- Endpoints related to healthy aging: No long-term intervention studies in non-diabetic healthy populations measuring mortality, cardiovascular events, or functional decline.
Is ALA Safe?
At 300–600 mg/day, ALA is considered likely safe in most people. Side effects at higher doses include nausea, rash, and in rare cases, hypoglycemia—particularly problematic in people with diabetes on insulin or sulfonylureas. ALA can enhance insulin action, so dose adjustments to diabetes medications may be necessary if you start supplementing. Additionally, ALA may deplete thiamine (vitamin B1) in susceptible individuals; if you have a known thiamine deficiency, consult a doctor before taking ALA. Finally, do not take ALA with meals, as food significantly reduces its absorption—take it on an empty stomach for optimal bioavailability.
Who Is ALA Most Relevant For?
The evidence base is strongest for people with metabolic dysfunction—specifically insulin resistance, metabolic syndrome, or prediabetes. ALA also remains most clinically tangible in diabetic neuropathy, where newer data is more practice-relevant than many older mechanistic papers. For healthy individuals interested in longevity and healthy aging, the evidence is much weaker. CoQ10, GlyNAC (NAC+glycine), and other compounds have stronger aging-related evidence. ALA may have a place in a metabolic-support stack, but it is not a foundational longevity intervention in the absence of metabolic disease.